In a post on X, Hims & Hers' chief executive, Andrew Dudum, said that the company will "continue to offer access to personalised treatments as allowed by law to meet patient needs," and will be "closely monitoring" the semaglutide supply chain, given that Novo Nordisk "stated two weeks ago that it would continue to have 'capacity limitations' and 'expected continued periodic supply constraints and related drug shortage notifications'." For its part, the FDA said it "has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved." The agency will continue to allow compounders to provide semaglutide to patients on a temporary basis "to avoid unnecessary disruption to patient treatment." State-licensed pharmacy or physician compounders can continue to do so until 22nd April, while outsourcing facilities have a deadline of 22nd May
It helps stop wrinkles and signs of aging for a firmer, more youthful look
It provides key insights into the GLP-1 segment, Peptide API manufacturing trends, and emerging therapeutic applications to help you identify high-value investment opportunities and optimize your market entry strategy
CNG DNG
PMID: 26607009 6 A case of atypical systemic primary carnitine deficiency in Saudi Arabia
Endometriosis is an oestrogen-dependent condition: the hormonal environment associated with it may influence weight distribution and body composition, though the precise mechanisms remain an active area of research
